Serono pays $44m to settle promotion of multiple sclerosis drugBMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d2922 (Published 10 May 2011) Cite this as: BMJ 2011;342:d2922
- Janice Hopkins Tanne
- 1New York
EMD Serono and its affiliates have agreed to pay $44.3m (£27.2m; €31.1m) to resolve allegations relating to the marketing of its multiple sclerosis drug Rebif (interferon beta-1a), the US Department of Justice announced on 4 May.
The department said that the settlement resolved allegations brought under the False Claims Act that Serono paid healthcare providers to promote or prescribe the drug from the time of its launch in January 2002 until December 2009.
The federal government will receive $34.6m and the states will receive $9.7m to resolve their claims under Medicare, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial